AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6348314 — intervention group
Group type: COMPARATOR
Intervention: sedative-benzodiazepines (eight months or more)
Number of subjects: 180
Study 3952641 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose-rate irradiation (Ra226)
Number of subjects: 299
Study 3952641 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose-rate irradiation (Ir192)
Number of subjects: 299
Study 3952641 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose-rate irradiation (Ir192) combined with percutaneous Co60 therapy
Number of subjects: 299
Study 3952641 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified high-dose-rate irradiation (Ir192) scheme (reduction of dose from 10 to 7 Gy)
Number of subjects: 299
Study 30390879 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Intermittent Training (HIIT) - 5 km running at 100% speed for 1 min interspersed with 1 min passive recovery, 3 times a week for 5 weeks
Number of subjects: 20
Study 30390879 — intervention group
Group type: COMPARATOR
Intervention: Steady-State Training (SST) - 5 km running at 70% of vV̇O2peak continuously, 3 times a week for 5 weeks
Number of subjects: 20
Study 29383331 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal oxygenation (recommended care)
Number of subjects: 4200
Study 29383331 — intervention group
Group type: COMPARATOR
Intervention: Strategy that permits hypoxia to SpO2 >= 80% (permissive hypoxia)
Number of subjects: 4200
Study 29383331 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow using AirVO2 TM
Number of subjects: 4200
Study 29383331 — intervention group
Group type: COMPARATOR
Intervention: Low flow delivery (routine care)
Number of subjects: 4200
Study 25912786 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition therapy (intensive, biometric parameter-oriented dietary counseling)
Number of subjects: 20
Study 25912786 — intervention group
Group type: COMPARATOR
Intervention: Control (regular dietary counseling)
Number of subjects: 20
Study 23682433 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg daily for 2 days
Number of subjects: 37
Study 23682433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 20648930 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 3000
Study 20648930 — intervention group
Group type: COMPARATOR
Intervention: Iron sucrose (ISC)
Number of subjects: 3000
Study 18580415 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-maximal-intensity (95% VO2R)
Number of subjects: 61
Study 18580415 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity (75% VO2R)
Number of subjects: 61
Study 18580415 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity (50% VO2R)
Number of subjects: 61
Study 18580415 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 61
Study 16545120 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of exercise therapy supervised by a physical therapist
Number of subjects: 136
Study 16545120 — intervention group
Group type: COMPARATOR
Intervention: Usual care (information and advice about the complaints only)
Number of subjects: 136
Study 14604454 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (0.5-3.0 mg/d) for 8 weeks
Number of subjects: 16
Study 14604454 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 16
Study 14604454 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 16
Study 14604454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10972850 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66
Number of subjects: 1207
Study 10972850 — intervention group
Group type: COMPARATOR
Intervention: EPI vaccines
Number of subjects: 1207
Study 8625432 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC with MORA in supported rest position
Number of subjects: 7
Study 8625432 — intervention group
Group type: EXPERIMENTAL
Intervention: MORA
Number of subjects: 7
Study 8625432 — intervention group
Group type: COMPARATOR
Intervention: Rest position
Number of subjects: 7
Study 8625432 — intervention group
Group type: COMPARATOR
Intervention: MVC with placebo
Number of subjects: 7
Study 8625432 — intervention group
Group type: COMPARATOR
Intervention: MVC in intercuspal position
Number of subjects: 7
Study 1728444 — intervention group
Group type: EXPERIMENTAL
Intervention: t-PA (0.49 MU/kg for 1 hour followed by 0.07 MU/kg per hour for 9 hours)
Number of subjects: 70
Study 1728444 — intervention group
Group type: EXPERIMENTAL
Intervention: t-PA
Number of subjects: 70
Study 1728444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 6329121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide
Number of subjects: 8
Study 6329121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin
Number of subjects: 8
Study 6329121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31079849 — intervention group
Group type: EXPERIMENTAL
Intervention: H10N8 100-µg IM dose
Number of subjects: 357
Study 31079849 — intervention group
Group type: EXPERIMENTAL
Intervention: H10N8 25-µg intradermal dose
Number of subjects: 357
Study 31079849 — intervention group
Group type: EXPERIMENTAL
Intervention: H7N9 IM doses of 10 µg
Number of subjects: 357
Study 31079849 — intervention group
Group type: EXPERIMENTAL
Intervention: H7N9 IM doses of 25 µg
Number of subjects: 357
Study 31079849 — intervention group
Group type: EXPERIMENTAL
Intervention: H7N9 IM doses of 50 µg
Number of subjects: 357
Study 31079849 — intervention group
Group type: EXPERIMENTAL
Intervention: H10N8 100 µg IM
Number of subjects: 357
Study 31079849 — intervention group
Group type: EXPERIMENTAL
Intervention: H7N9 50 µg
Number of subjects: 357
Study 30109669 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD)
Number of subjects: 86
Study 30109669 — intervention group
Group type: COMPARATOR
Intervention: Low Calorie Diet (LCD)
Number of subjects: 86
Study 26938706 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction models for disease progression
Number of subjects: 1113
Study 24615194 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated conformal radiotherapy (RT) combined with chemotherapy (CHT)
Number of subjects: 100
Study 23031623 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (2 mg)
Number of subjects: 134
Study 20862644 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (dose-escalation)
Number of subjects: 0
Study 20862644 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of SSRIs
Number of subjects: 0
Study 17823083 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride (60 mg/day)
Number of subjects: 22
Study 17823083 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-osteoporotic postmenopausal women)
Number of subjects: 22
Study 16200917 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological stress control program (interview, video, informative literature, anxiety control techniques)
Number of subjects: 74
Study 16200917 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychological intervention)
Number of subjects: 74
Study 11837381 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 mg valsartan tablet
Number of subjects: 40
Study 11837381 — intervention group
Group type: COMPARATOR
Intervention: 2 x 160 mg valsartan capsules
Number of subjects: 40
Study 10214735 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release physostigmine 30 mg daily
Number of subjects: 475
Study 10214735 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release physostigmine 36 mg daily
Number of subjects: 475
Study 10214735 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release physostigmine (both dosages)
Number of subjects: 475
Study 10214735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 475
Study 7609260 — intervention group
Group type: EXPERIMENTAL
Intervention: Escort strategy (child escorted to a nearby pediatric clinic for immunization)
Number of subjects: 836
Study 7609260 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher incentive strategy (family returns monthly for WIC food vouchers until child is immunized)
Number of subjects: 836
Study 7609260 — intervention group
Group type: COMPARATOR
Intervention: Referral strategy (family passively referred for immunization)
Number of subjects: 836
Study 2649811 — intervention group
Group type: EXPERIMENTAL
Intervention: Yuzpe's postcoital method (0.1 mg ethinyloestradiol and 1 mg d1‐norgestrel taken within 72 hours of unprotected intercourse and repeated 12 hours later)
Number of subjects: 909
Study 2649811 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel pills
Number of subjects: 909
Study 2649811 — intervention group
Group type: EXPERIMENTAL
Intervention: Yuzpe's method taken after 48 hours
Number of subjects: 909
Study 2649811 — intervention group
Group type: EXPERIMENTAL
Intervention: Yuzpe's method taken before 12 hours
Number of subjects: 909
Study 2649811 — intervention group
Group type: EXPERIMENTAL
Intervention: Yuzpe's method (any timing)
Number of subjects: 909
Study 367425 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa treatment for hypertension in pregnancy
Number of subjects: 0
Study 367425 — intervention group
Group type: COMPARATOR
Intervention: Treated group (methyldopa)
Number of subjects: 0
Study 31405797 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant use
Number of subjects: 403
Study 31405797 — intervention group
Group type: COMPARATOR
Intervention: Black participants
Number of subjects: 403
Study 31405797 — intervention group
Group type: COMPARATOR
Intervention: Hispanic participants
Number of subjects: 403
Study 28135846 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium monotherapy (N=49)
Number of subjects: 142
Study 28135846 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline monotherapy (N=45)
Number of subjects: 142
Study 28135846 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium/Sertraline combination (N=48)
Number of subjects: 142
Study 28135846 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 142
Study 28135846 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium/Sertraline combination
Number of subjects: 142
Study 27557302 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab (16 mg per kilogram of body weight) in combination with bortezomib (1.3 mg per square meter) and dexamethasone (20 mg)
Number of subjects: 498
Study 27557302 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib (1.3 mg per square meter) and dexamethasone (20 mg) alone
Number of subjects: 498
Study 27557302 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab group
Number of subjects: 498
Study 27557302 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 498
Study 24858505 — intervention group
Group type: EXPERIMENTAL
Intervention: Forest environment
Number of subjects: 36
Study 24858505 — intervention group
Group type: COMPARATOR
Intervention: Urban environment
Number of subjects: 36
Study 21843878 — intervention group
Group type: EXPERIMENTAL
Intervention: Slope walking
Number of subjects: 12
Study 21843878 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair walking
Number of subjects: 12
Study 21843878 — intervention group
Group type: COMPARATOR
Intervention: Level walking
Number of subjects: 12
Study 19092676 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 62
Study 19092676 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 62
Study 17284894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (90 mg)
Number of subjects: 60
Study 17284894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15317980 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate training program (n=8)
Number of subjects: 12
Study 15317980 — intervention group
Group type: COMPARATOR
Intervention: No training intervention (n=4)
Number of subjects: 12
Study 11564000 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide 100 mg, three times a day for 8 weeks
Number of subjects: 557
Study 11564000 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide 200 mg, three times a day for 8 weeks
Number of subjects: 557
Study 11564000 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide 100 mg
Number of subjects: 557
Study 11564000 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide 200 mg
Number of subjects: 557
Study 11564000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 557
Study 9577366 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO Colour Scale
Number of subjects: 1213
Study 8161290 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 34
Study 8161290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 3664914 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine 20 mg IV
Number of subjects: 150
Study 3664914 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine 40 mg IV
Number of subjects: 150
Study 3664914 — intervention group
Group type: COMPARATOR
Intervention: meperidine 75 mg IM
Number of subjects: 150
Study 31667802 — intervention group
Group type: EXPERIMENTAL
Intervention: HPyV10 detected in stool specimens from children with acute diarrhoea
Number of subjects: 566
Study 31667802 — intervention group
Group type: COMPARATOR
Intervention: HPyV10 detected in stool specimens from healthy asymptomatic children
Number of subjects: 566
Study 31667802 — intervention group
Group type: EXPERIMENTAL
Intervention: HPyV11 detected in stool specimens from children with acute diarrhoea
Number of subjects: 566
Study 31667802 — intervention group
Group type: COMPARATOR
Intervention: HPyV11 detected in stool specimens from healthy asymptomatic children
Number of subjects: 566
Study 29471865 — intervention group
Group type: EXPERIMENTAL
Intervention: NECT (nifurtimox-eflornithine combination) - 200 mg/kg eflornithine infusions every 12 hours for 7 days and 8 hourly oral nifurtimox at 5 mg/kg for 10 days
Number of subjects: 109
Study 29471865 — intervention group
Group type: COMPARATOR
Intervention: Eflornithine monotherapy - 100 mg/kg every 6 hours for 14 days
Number of subjects: 109
Study 27177316 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment interruption
Number of subjects: 42
Study 27177316 — intervention group
Group type: COMPARATOR
Intervention: Continued ART
Number of subjects: 42
Study 24747553 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical vaginal cuff closure
Number of subjects: 52
Study 24747553 — intervention group
Group type: COMPARATOR
Intervention: Horizontal vaginal cuff closure
Number of subjects: 52
Study 22404798 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking + Doing = Daring (TDD)
Number of subjects: 120
Study 22404798 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 120
Study 21189165 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol® (Pyc)
Number of subjects: 0
Study 21189165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17497585 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (6%)
Number of subjects: 15
Study 17497585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 15826330 — intervention group
Group type: EXPERIMENTAL
Intervention: Health belief model (HBM) based intervention
Number of subjects: 833
Study 12133045 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 668
Study 12133045 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 25 mg
Number of subjects: 668
Study 12133045 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan 100 mg
Number of subjects: 668
Study 12133045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 668
Study 8647515 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 400 mg/day
Number of subjects: 59
Study 8647515 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 300 mg/day
Number of subjects: 59
Study 8647515 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole 50 mg/day (control)
Number of subjects: 59
Study 2213744 — intervention group
Group type: EXPERIMENTAL
Intervention: Stripping of the membranes
Number of subjects: 99
Study 2213744 — intervention group
Group type: COMPARATOR
Intervention: Control (non-stripped group)
Number of subjects: 99
Study 24563 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen 1 mg b.i.d. (Group I)
Number of subjects: 36
Study 24563 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen 2 mg b.i.d. (Group II)
Number of subjects: 36
Study 24563 — intervention group
Group type: COMPARATOR
Intervention: Clemastine 1 mg b.i.d. (Group III)
Number of subjects: 36
Study 30586575 — intervention group
Group type: EXPERIMENTAL
Intervention: Exendin-9,39 infusion at 300 pmol/kg/min for 6 h
Number of subjects: 12
Study 30586575 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 12
Study 28779304 — intervention group
Group type: EXPERIMENTAL
Intervention: Peloid therapy (10 sessions over 2 weeks, 5 sessions a week)
Number of subjects: 63
Study 28779304 — intervention group
Group type: COMPARATOR
Intervention: Home exercise program (control group)
Number of subjects: 63
Study 28779304 — intervention group
Group type: COMPARATOR
Intervention: Peloid therapy vs Control group
Number of subjects: 63
Study 27670399 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management intervention
Number of subjects: 114
Study 27670399 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 114
Study 23711809 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathrombus urokinase (200,000 U)
Number of subjects: 102
Study 23711809 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 102
Study 21854611 — intervention group
Group type: EXPERIMENTAL
Intervention: Health risk factors (smoking, risky drinking, overweight/obesity, etc.)
Number of subjects: 7906
Study 21854611 — intervention group
Group type: EXPERIMENTAL
Intervention: Health risk factors (substance use, nutrition, physical inactivity)
Number of subjects: 7906
Study 21854611 — intervention group
Group type: EXPERIMENTAL
Intervention: Health risk factors (various)
Number of subjects: 7906
Study 19647409 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler Imaging (TDI)
Number of subjects: 90
Study 19647409 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-Time Three-Dimensional Echocardiography (RT3DE)
Number of subjects: 90
Study 19647409 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 90
Study 19647409 — intervention group
Group type: EXPERIMENTAL
Intervention: TDI
Number of subjects: 90
Study 19647409 — intervention group
Group type: EXPERIMENTAL
Intervention: RT3DE
Number of subjects: 90
Study 17919093 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy, counseling, and self-help written materials
Number of subjects: 95
Study 14758135 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 years of tamoxifen after CNF chemotherapy and ovarian ablation (Group B)
Number of subjects: 456
Study 14758135 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 cycles of CNF followed by 5 years of tamoxifen (Group D)
Number of subjects: 456
Study 14758135 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 years of tamoxifen (Group C)
Number of subjects: 456
Study 14758135 — intervention group
Group type: COMPARATOR
Intervention: CNF chemotherapy
Number of subjects: 456
Study 11708731 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality treatment
Number of subjects: 28
Study 11708731 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral psychonutritional groups
Number of subjects: 28
Study 9812083 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside monitoring
Number of subjects: 1713
Study 9812083 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring
Number of subjects: 1713
Study 7928850 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (25 mg of Zn and 1.5 mg of copper)
Number of subjects: 5
Study 7928850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 2789542 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 26
Study 2789542 — intervention group
Group type: COMPARATOR
Intervention: Alpha-methyldopa
Number of subjects: 26
Study 1092511 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline in combination with alcohol (0.5 gm/kg)
Number of subjects: 40
Study 1092511 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin in combination with alcohol (0.5 gm/kg)
Number of subjects: 40
Study 1092511 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline and Doxepin in combination with alcohol (0.5 gm/kg)
Number of subjects: 40
Study 1092511 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline and Chlorimipramine
Number of subjects: 40
Study 31119849 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 77
Study 30885158 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (33 villages)
Number of subjects: 66
Study 30885158 — intervention group
Group type: COMPARATOR
Intervention: Control group (33 villages)
Number of subjects: 66
Study 28637922 — intervention group
Group type: EXPERIMENTAL
Intervention: Lampalizumab administered by intravitreal injection monthly
Number of subjects: 123
Study 28637922 — intervention group
Group type: EXPERIMENTAL
Intervention: Lampalizumab administered by intravitreal injection every other month
Number of subjects: 123
Study 28637922 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 123
Study 28637922 — intervention group
Group type: EXPERIMENTAL
Intervention: Lampalizumab (monthly) in CFI risk-allele carriers
Number of subjects: 123
Study 24824415 — intervention group
Group type: EXPERIMENTAL
Intervention: World Health Organization Surgical Safety Checklist (SSC)
Number of subjects: 4475
Study 24824415 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4475
Study 22612171 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent motor tasks
Number of subjects: 0
Study 22612171 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent verbal tasks
Number of subjects: 0
Study 22612171 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent visual tasks
Number of subjects: 0